Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 9/20 | 0.52 |
| ▸ | F2 | P00734 | 4/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4967519 | 0.86 | CNR2 (0.55) | LMNASMN1; SMN2PAX8POLBCNR2 | |
| SCHEMBL4966026 | 0.85 | CNR2 (0.64) | LMNASMN1; SMN2PAX8POLBCNR2 | |
| SCHEMBL4965771 | 0.85 | CNR2 (0.72) | LMNASMN1; SMN2CNR2 | |
| SCHEMBL4966045 | 0.85 | CNR2 (0.61) | LMNASMN1; SMN2PAX8POLBCNR2 | |
| SCHEMBL5434197 | 0.84 | LMNA (0.54) | LMNASMN1; SMN2PAX8POLBCNR2 | |
| SCHEMBL4966119 | 0.84 | CNR2 (0.65) | LMNASMN1; SMN2PAX8POLBCNR2 | |
| SCHEMBL4967004 | 0.84 | CNR2 (0.58) | LMNASMN1; SMN2PAX8POLBCNR2 | |
| SCHEMBL4965990 | 0.82 | CNR2 (0.68) | SMN1; SMN2CNR2 | |
| SCHEMBL4968467 | 0.82 | CNR2 (0.60) | LMNASMN1; SMN2PAX8POLBCNR2 | |
| SCHEMBL4965482 | 0.80 | CNR2 (0.67) | CNR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221178-A1 | Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | claimed |
| EP-1670790-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-08-20 | — | — | EP | claimed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | claimed |
| EP-1673369-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-28 | — | — | EP | claimed |
| EP-1670790-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-21 | — | — | EP | claimed |
| WO-2005030761-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | claimed |
| WO-2005030762-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | claimed |
| US-20080221178-A1 | Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221178-A1 | Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221178-A1 | Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| EP-1670790-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
| EP-1673369-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-28 | — | — | EP | disclosed |
| EP-1670790-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030761-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030762-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | RB1, CYP2C19, ADRB3 | LMNA 1900/4885SMN1; SMN2 1109/4885PAX8 3497/4885 |
| US-20080221178-A1 | Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof | TBXA2R, CYP2C19, CYP3A43 | LMNA 2485/4885SMN1; SMN2 1400/4885PAX8 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.